{"product_id":"sugemalimab-cejemly","title":"Cejemly (Sugemalimab)","description":"\u003ch2\u003eAbout Cejemly® (Sugemalimab)\u003c\/h2\u003e\u003cp\u003eThe anti-PD-L1 monoclonal antibody sugemalimab was discovered by CStone using the OmniRat\u003csup\u003e®\u003c\/sup\u003e transgenic animal platform, which allows creation of fully human antibodies in one step. Sugemalimab is a fully human, full-length anti-PD-L1 immunoglobulin G4 (IgG4) monoclonal antibody, which may reduce the risk of immunogenicity and toxicity for patients, a unique advantage over similar drugs.\u003c\/p\u003e\u003ch2\u003e\u003cspan id=\"Approval\"\u003eApproval\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eThe NMPA of China has approved sugemalimab for four indications:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eIn combination with chemotherapy for first-line treatment of patients with metastatic squamous and non-squamous NSCLC.\u003c\/li\u003e\n\u003cli\u003eFor the treatment of patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy.\u003c\/li\u003e\n\u003cli\u003eFor the treatment of patients with relapsed or refractory extranodal NK\/T-cell lymphoma.\u003c\/li\u003e\n\u003cli\u003eIn combination with fluorouracil and platinum-based chemotherapy for first-line treatment of patients with unresectable locally advanced, recurrent or metastatic ESCC.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cspan class=\"LEwnzc Sqrs4e\"\u003eJuly 26, 2024 — \u003c\/span\u003eCStone Announces European Commission (EC) Approval of \u003cem\u003eCejemly\u003c\/em\u003e® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eSugemalimab sold as brand name 择捷美® in china.\u003c\/li\u003e\n\u003cli\u003eSugemalimab sold as brand name Cejemly® in European Union.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eReference: 《\u003ca href=\"https:\/\/www.prnewswire.com\/news-releases\/cstone-announces-european-commission-approval-of-sugemalimab-cejemly-as-first-line-treatment-for-non-small-cell-lung-cancer-302207524.html\"\u003eCStone Announces European Commission Approval of Sugemalimab (Cejemly®) as First-Line Treatment for Non-Small Cell Lung Cancer\u003c\/a\u003e 》\u003c\/p\u003e","brand":"CStone Pharmaceuticals","offers":[{"title":"Default Title","offer_id":44797945970731,"sku":"RL29","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-07-262.png?v=1787022066","url":"https:\/\/xomeds.com\/products\/sugemalimab-cejemly","provider":"XOMEDS","version":"1.0","type":"link"}